Abstract
A specific, robust, and rapid UV-HPLC method was developed for the assay of daclatasvir (DCV) in pharmaceutical formulation in the presence of potential degradation products using quality-by-design approach. The impurity profile of DCV was studied via forced degradation procedures with subsequent characterization of the resultant degradation products using LC–MS. Central composite design with response surface methodology was utilized to simultaneously optimize four chromatographic factors: pH, elution temperature, flow rate, and organic modifier %. The first order, interaction, and quadratic effects of those four factors were evaluated for 16 responses of eight peaks “resolution (7), number of theoretical plates (8), run time (1)”. Optimum separation was achieved using Eclipse plus RP C18 column, mobile phase consisting of methanol: 0.025 M phosphate buffer pH 7.0 (58: 42 v/v), flow rate of 1.5 mL min−1at 40 °C, and detection at 303 nm. The optimized method was validated according to ICH guidelines and applied to determine DCV in pharmaceutical formulation. DCV response was linear (r = 0.9999) in the range 1.5–90 µg mL−1; inter-day and intra-day precisions were 0.28% and 0.25%, respectively, and independent t test indicated non-significant difference between inter- and intra-day means; accuracy was 100.49 ± 0.92%.
Similar content being viewed by others
References
Mohamed AA et al (2015) Hepatitis C virus: a global view. World J Hepatol 7(26):2676
Jiang H, Kandoussi H, Zeng J, Wang J, Demers R, Eley T et al (2015) Multiplexed LC-MS/MS method for the simultaneous quantitation of three novel hepatitis C antivirals, daclatasvir, asunaprevir, and beclabuvir in human plasma. J Pharm Biomed Anal 107:409–418
Tellinghuisen TL, Marcotrigiano J, Gorbalenya AE, Rice CM (2004) The NS5A protein of hepatitis C virus is a zinc metalloprotein. J Biol Chem 279(47):48576–48587
He Y, Staschke KA, Tan SL (2006) HCV NS5A: a multifunctional regulator of cellular pathways and virus replication. In: Tan SL (ed) Hepatitis C viruses: genomes and molecular biology, chap 9. Horizon Bioscience, Norfolk
Fontana R, Hughes E, Bifano M, Appelman H, Dimitrova D, Hindes R et al (2013) Sofosbuvir and daclatasvir combination therapy in a liver transplant recipient with severe recurrent cholestatic hepatitis C. Am J Transplant 13(6):1601–1605
Pol S, Ghalib RH, Rustgi VK, Martorell C, Everson GT, Tatum HA et al (2012) Daclatasvir for previously untreated chronic hepatitis C genotype-1 infection: a randomised, parallel-group, double-blind, placebo-controlled, dose-finding, phase 2a trial. Lancet Infect Dis 12(9):671–677
Chakravarthy VA, Sailaja B (2016) Method development and validation of assay and dissolution methods for the estimation of daclatasvir in tablet dosage forms by reverse phase HPLC. Eur J Pharm Med Res 3:356–364
Satyanarayana L, Sandeepthi N (2018) The estimation of daclatasvir in tablet dosage form by RP-HPLC. Int J Pharma Res Health Sci 6(1):2212–2215
Dandamudi SP, Battineni JK, Bakshi V, Peddapalli H, Boggula N (2018) Validated RP-HPLC method for estimation of daclatasvir in tablet dosage form. Int J Adv Res Dev 3(2):1170–1174
Sumathi K, Thamizhvanan K, Vijayraj S (2016) Development and validation of stability indicating RP-HPLC method for the estimation of daclatasvir in bulk and formulation. Pharm Lett 8(15):107–113
Baker M, El-Kafrawy D, Mahrous M, Belal T (2017) Validated stability-indicating HPLC-DAD method for determination of the recently approved hepatitis C antiviral agent daclatasvir. Elsevier, Amsterdam, pp 176–184
Ragab GHA, Saleh H, Othman MA (2017) Stability indicating HPLC method development and validation for determination of daclatasvir in pure and tablets dosage forms. INDO Am J Pharm Sci 3:1565–1572
Zaman B, Hassan W (2018) Development of stability indicating HPLC–UV method for determination of daclatasvir and characterization of forced degradation products. Chromatographia 81(5):785–797
Nannetti G, Messa L, Celegato M, Pagni S, Basso M, Parisi SG et al (2017) Development and validation of a simple and robust HPLC method with UV detection for quantification of the hepatitis C virus inhibitor daclatasvir in human plasma. J Pharm Biomed Anal 134:275–281
Aboshabana R, Shalan S, Eid M, El-Enany N (2018) Two validated spectrofluorimeteric and high performance liquid chromatography (HPLC) methods with fluorescence detection for the analysis of a new anti-hepatitis C drug, daclatasvir hydrochloride, in raw material or tablet form and in biological fluids. Luminescence 33(8):1333–1345
Atia NN, El-Shaboury SR, El-Gizawy SM, Abo-Zeid MN (2018) Simultaneous quantitation of two direct acting hepatitis C antivirals (sofosbuvir and daclatasvir) by an HPLC-UV method designated for their pharmacokinetic study in rabbits. J Pharm Biomed Anal 158:88–93
Abdallah OM, Abdel-Megied AM, Gouda AS (2018) Development and validation of LC-MS/MS method for simultaneous determination of sofosbuvir and daclatasvir in human plasma: application to pharmacokinetic study. Biomed Chromatogr 32(6):e4186
Kekan V, Gholve S, Bhusnure O (2017) Development, validation and stability study of UV spectrophotometric method for determination of daclatasvir in bulk and pharmaceutical dosage forms. Int J Chemtech Res 10:281–287
Schweitzer M, Pohl M, Hanna-Brown M, Nethercote P, Borman P, Hansen G et al (2010) Implications and opportunities of applying QbD principles to analytical measurements. Pharm Technol 34(2):52–59
Huang J, Goolcharran C, Ghosh K (2011) A quality by design approach to investigate tablet dissolution shift upon accelerated stability by multivariate methods. Eur J Pharm Biopharm 78(1):141–150
Jadhav ML, Tambe SR, Girase MV. Analytical quality by design approach for development of uv spectrophotometric methods in the estimation of trospium chloride from capsule dosage form. Int J Pharm Pharm Sci. 2014;6(10)
Wang L, Chen T, Zeng S, Qu H (2014) Quality by design study of the direct analysis in real time mass spectrometry response. J Am Soc Mass Spectrom 25(2):278–285
Raman N, Mallu UR, Bapatu HR (2015) Analytical quality by design approach to test method development and validation in drug substance manufacturing. J Chem 2015:1–8
Krull I, Swartz M, Turpin J, Lukulay PH, Verseput R (2008) A quality-by-design methodology for rapid LC method development, part I. LCGC N Am 26:1190–1197
Krull I, Swartz M, Turpin J, Lukulay PH, Verseput R (2009) A quality-by-design methodology for rapid LC method development, part II. LCGC N Am 27:48–61
Ling V, McBrien MM (2011) A quality by design approach to chromatographic method development. LCGC Column 7:16–20
Vogt FG, Kord AS (2011) Development of quality-by-design analytical methods. J Pharm Sci 100(3):797–812
Karmarkar S, Garber R, Genchanok Y, George S, Yang X, Hammond R (2011) Quality by design (QbD) based development of a stability indicating HPLC method for drug and impurities. J Chromatogr Sci 49(6):439–446
Ayre A, Mane P, Ghude K, Nemade M, Gide P (2014) Implementing quality by design—a methodical approach in the RP-HPLC method development process. Int J Adv Pharm Anal 4(1):01–06
Gad M, Zaazaa HE, Amer SM, Korany MA (2017) Quality by design approach for establishment of stability indicating method for determination of Cefditoren Pivoxil. J Pharm Anal Insights 2(1)
Lin Y-H, Yang Y-H, Wu S-M (2007) Experimental design and capillary electrophoresis for simultaneous analysis of arbutin, kojic acid and hydroquinone in cosmetics. J Pharm Biomed Anal 44(1):279–282
Ragonese R, Macka M, Hughes J, Petocz P (2002) The use of the Box–Behnken experimental design in the optimisation and robustness testing of a capillary electrophoresis method for the analysis of ethambutol hydrochloride in a pharmaceutical formulation. J Pharm Biomed Anal 27(6):995–1007
Gilmour SG (2006) Response surface designs for experiments in bioprocessing. Biometrics 62(2):323–331
Bezerra MA, Santelli RE, Oliveira EP, Villar LS, Escaleira LA (2008) Response surface methodology (RSM) as a tool for optimization in analytical chemistry. Talanta 76(5):965–977
Derringer G (1980) Simultaneous optimization of several response variables. J Qual Technol 12:214–219
Bourguignon B, Massart D (1991) Simultaneous optimization of several chromatographic performance goals using Derringer’s desirability function. J Chromatogr A 586(1):11–20
ICH Harmonized Tripartite Guideline (2005) Q2B validation of analytical procedures: methodology. Switzerland, Geneva
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Conflict of interest
The authors declare that they have no conflict of interest.
Ethical approval
This article does not contain any studies with human participants or animals performed by any of the authors.
Additional information
Publisher's Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Electronic supplementary material
Below is the link to the electronic supplementary material.
Rights and permissions
About this article
Cite this article
Gad, M., Hassan, S.A., Zaazaa, H.E. et al. Multivariate Development and Optimization of Stability Indicating Method for Determination of Daclatasvir in Presence of Potential Degradation Products. Chromatographia 82, 1641–1652 (2019). https://doi.org/10.1007/s10337-019-03793-y
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s10337-019-03793-y